Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors
Phase II, 2-cohort, single arm trial treated with the combination of the following two agents:

1. Pembrolizumab (MK3475) 200mg, every three weeks, iv
2. Docetaxel 75mg/m2, every three weeks, iv
Thyroid Cancer|Salivary Gland Cancer
DRUG: Pembrolizumab|DRUG: Docetaxel
Rate of response, From the start of treatment until the first documented record of response, up to 100 months, whichever comes first.
Number of adverse events, Up to 24 months.|Overall rate of survival, From the start of treatment until the first record of death by any cause, up to 100 months, whichever comes first.|Rate of progression free survival, From the start of treatment to the first record of disease progression or death by any cause, up to 100 months, whichever comes first.
Eligible patients will be divided into two cohorts.

Cohort 1: salivary gland tumors without SOC treatment option Cohort 2: 'aggressive' thyroid cancer without SOC treatment option

Both cohorts will undergo a biopsy and will begin immunotherapy plus chemotherapy. Pembrolizumab and steroid sparing taxane: docetaxel will be given every three weeks for 3 to 6 cycles. For accessible tumors only, at week three patients will receive an on-treatment biopsy.

Patients will move on to immunotherapy maintenance after completing their cycles. Pembrolizumab will be given every three weeks until disease progression or up to 35 cycles (about 2 years).